$Benitec Biopharma (BNTC.US)$ NEWS Benitec Biopharma Reports...
NEWS
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study
Improvements in swallowing function demonstrated in multiple measures following BB-301 administration
No serious adverse events reported, with transient GERD resolved with common medications
Encouraging early clinical trial results offering hope to patients and caregivers
BB-301 granted Orphan Drug designation by FDA and EMA COMP
Virtual R&D event featuring OPMD key opinion leaders held on April 18, 2024
Positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study
Improvements in swallowing function demonstrated in multiple measures following BB-301 administration
No serious adverse events reported, with transient GERD resolved with common medications
Encouraging early clinical trial results offering hope to patients and caregivers
BB-301 granted Orphan Drug designation by FDA and EMA COMP
Virtual R&D event featuring OPMD key opinion leaders held on April 18, 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
424Followers
64Following
2736Visitors
Follow